The First-Line Treatment for Advanced Pancreatic Cancer
Abstract
Pancreatic cancer is sometimes called a "silent killer" because it is often not diagnosed until it is advanced. It remains the fourth leading cause of cancer-related death in the United States. Gemcitabine has been the front line therapy for advanced pancreatic cancer over the past 10 years. Over this time period, survival benefit has not been able to improve substantially from studies of gemcitabine-based combination therapy. A breakthrough to improve treatment options in this setting is needed. In the 2010 ASCO Gastrointestinal Cancers Symposium in Orlando, Florida, USA, several abstracts were presented to explore new agents or combinations as first-line therapy in locally advanced or metastatic settings. In this article, we review and summarize the findings from these studies.
Image: Yale-New Haven Hospital. New Haven, CT, USA.
Downloads
References
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-49. [PMID 19474385] (FULL TEXT: http://caonline.amcancersoc.org/cgi/content/full/59/4/225)
National Cancer Institute. Pancreatic Cancer Treatment (PDQ®). Accessed 04 Feb 2010. (FULL TEXT: http://www.cancer.gov/cancertopics/pdq/treatment/pancreatic/HealthProfessional/page2)
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. [PMID 9196156] (FULL TEXT: http://jco.ascopubs.org/cgi/reprint/15/6/2403.pdf)
Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010 Jan 26. [PMID 20101258] (FULL TEXT: http://www.nature.com/nrclinonc/journal/vaop/ncurrent/full/nrclinonc.2009.236.html)
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6. [PMID 17452677] (FULL TEXT: http://jco.ascopubs.org/cgi/content/full/25/15/1960)
Javle MM, Varadhachary GR, Bhosale P, Ukegbu L, Overman MJ, Shroff RT, et al. Phase I study of MK-0646, a humanized monoclonal antibody against IGF-1R in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced previously untreated pancreatic cancer. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 131. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2257)
Philip PA, Goldman BH, Ramanathan RK, Lenz, Lowy AM, Whitehead RP, et al. Phase I trial of combination gemcitabine, erlotinib (NSC-718781), and IMC-A12 (NSC-742460) as first-line treatment in patients with metastatic pancreatic cancer: Southwest Oncology Group study S0727. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 233. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2202)
Francois E, Bennouna J, Etienne-Grimaldi M, Follana P, Senellart H, Mari V, et al. Phase I clinical trial with gemcitabine (Gem), capecitabine (Cap), and erlotinib (E) combination in advanced pretreated pancreatic carcinoma. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 245. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1989)
Geissler M, Hofheinz R, Moehler MH, Klöppel G, Bitzer M, Boeck SH, et al. Trastuzumab and capecitabine in patients with HER2-expressing metastatic pancreatic cancer: A multicenter phase II study of the AIO pancreatic cancer group (on behalf of the German AIO group [AIO PK-0204]). 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 200. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1919)
Backlund DC, Goff LW, Chan E, Shyr Y, Conkright WA, Cornelius LA,et al. A phase II trial of sorafenib (S) and erlotinib (E) in unresectable pancreas cancer: Preliminary results. 2010 ASCO Gastrointestinal Cancers Symposium. Abstract No. 264. (FULL TEXT: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=1830)
Copyright (c) 2010 Man Yee Merl, Jia Li, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.